Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm Completes Acquisition of TissueInformatics

NEW YORK, March 12 (GenomeWeb News) - Paradigm Genetics has closed its acquisition of TissueInformatics, the company said yesterday.

 

Paradigm will issue approximately 3.4 million shares of its common stock to TissueInformatics shareholders immediately, valued at about $4.5 million, based on yesterday's closing price of Paradigm. Depending on whether TissueInformatics reaches certain revenue targets and obtains new research contracts before the end of the year, Paradigm will offer shareholders another 2.7 million shares.

 

In addition, Paradigm will assume all of TissueInformatics' outstanding options and warrants, equivalent to approximately 385,000 shares of Paradigm's common stock if TissueInformatics reaches its milestones. All shares will be locked up for one year after the date of closing.

 

Paradigm, based in Research Triangle Park, said it will maintain TissueInformatics' facility in Pittsburgh, Pa. Following the acquisition, first announced in January, Paradigm has 212 employees in total.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.